| Literature DB >> 32784487 |
Komal Waqas1, Jinluan Chen1,2, Bram C J van der Eerden1, M Arfan Ikram2, André G Uitterlinden1,2, Trudy Voortman2, M Carola Zillikens1.
Abstract
Animal studies suggest a role for dietary advanced glycation end-products (dAGEs) in bone health, but human studies on dAGEs in relation to bone are lacking. We aimed to study whether dAGEs intake is associated with the parameters of bone strength namely, bone mineral density (BMD), prevalent vertebral (VFs), and major osteoporotic fractures (MOFs = hip, wrist, proximal humerus, and clinical VFs). 3949 participants (mean age 66.7 ± 10.5 years) were included from a Rotterdam study for whom Carboxymethyllysine (CML-a dietary AGE) was estimated from food frequency questionnaires combined with dAGEs databases. Multivariable linear and logistic regression models were performed adjusting for age, sex, energy intake, dietary quality, physical activity, diabetes, smoking, renal function, and cohort effect and for models on fractures, subsequently for BMD. We observed no association of CML with BMD at both femoral neck (β = -0.006; p = 0.70) and lumbar spine (β = -0.013; p = 0.38). A higher intake of CML was linearly associated with VFs (Odds ratio, OR = 1.16, 95% CI (1.02-1.32) and a similar but non-significant trend with MOFs (OR = 1.12 (0.98-1.27). Additional adjustment for BMD did not change the associations. Our results imply a positive association between dietary intake of CML and VFs independent of BMD. Future studies are needed in order to elucidate whether associations found are causal.Entities:
Keywords: bone mineral density; dietary advanced glycation end-products osteoporosis; fractures; trabecular bone score
Mesh:
Substances:
Year: 2020 PMID: 32784487 PMCID: PMC7468958 DOI: 10.3390/nu12082377
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flowchart of participant inclusion from the Rotterdam Study. CML, Carboxymethyllysine; FFQ, food frequency questionnaire; dAGEs, dietary advanced glycation end-products.
Demographic and clinical characteristics of total participants with complete data and a comparison between subjects with (T2DM) and without type 2 diabetes mellitus (non-T2DM).
| Total Participants | T2DM ( | Non-T2DM ( | |
|---|---|---|---|
| CML (mg/day, energy adjusted) | 2.42 ± 0.88 | 2.49 ± 0.93 | 2.41 ± 0.86 |
| MGH1 (mg/day, energy adjusted) | 28.4 ± 7.73 | 29.1 ±7.8 * | 28.3 ± 7.7 |
| CEL (mg/day, energy adjusted) | 2.42 ± 0.87 | 2.57 ± 0.97 * | 2.39 ± 0.86 |
| Age (years) | 66.7 ± 10.5 | 72.0 ± 9.2 * | 66.2 ± 10.6 |
| Males, | 1703 (43%) | 235 (49.7%) * | 1469 (42.2%) |
| BMI (kg/m2) | 27.4 ± 4.2 | 29.7 ± 4.8 * | 27.0 ± 3.97 |
|
| 77.9 ± 14.9 | 77.6 (22.9) * | 79.5 (19.6) * |
| eGFR < 60, | 466 (12%) | 92 (19.5%) * | 378 (10.9%) |
| Never smokers, (%) | 32% | 27.7% | 33.1% |
| Ex-smokers, (%) | 52% | 59.0% | 50.8% |
| Current smokers, (%) | 16% | 13.3% | 16.1% |
| Total energy intake, kcal/day | 2154 ± 683 | 2045 ± 690 * | 2169 ± 680 |
| Fat intake, g/d | 77.9 ± 35.4 | 74.2 ± 35.1 | 77.9 ± 34.7 |
| carbohydrate intake, g/day | 243.0 ± 87.0 | 229.6 ± 87.8 * | 245.1 ± 85.3 |
| protein intake, g/day | 82.6 ± 26.2 | 81.6 ± 27.9 | 82.7 ± 25.5 |
| Physical activity (MET hours/week) | 41.5 (64.6) | 31.6 (54.9) * | 42.7 (65.8) |
| Major osteoporotic fractures, | 334 (8.5%) | 42 (9%) | 292 (8.4%) |
| Vertebral fractures, | 296 (7.5%) | 261 (7.5%) | 35 (7.4%) |
| Femoral neck BMD, g/cm2 | 0.901 ± 0.137 | 0.916 ± 0.142 * | 0.899 ±0.136 |
| Lumbar spine BMD, g/cm2 | 1.140 ± 0.217 | 1.194 ± 0.215 * | 1.132 ± 0.216 |
| TBS (unitless) | 1.311 ± 0.101 | 1.297 ± 0.107 | 1.313 ± 0.101 |
Carboxymethyllysine, CML; Carboxyethyllysine, CEL; Methylglyoxal-derived hydroimidazolones, MG-H1; Dietary advanced glycation end-products, dAGE; Body mass index, BMI; effective glomerular filtration rate, eGFR; Bone mineral density, BMD; trabecular bone score, TBS; major osteoporotic fractures, MOFs; Vertebral fractures, VFs; Data are presented as mean ± SD, median (interquartile range) and number (%). * Represents a p-value < 0.05 between subjects with T2DM and non-T2DM.
Association of energy-adjusted carboxymethyllysine (CML) with femoral neck and lumbar spine bone mineral density (BMD) and trabecular bone score (TBS) in the whole population (N = 3949).
| Outcome | Standardized Coefficient β ( | ||
|---|---|---|---|
| Model 1 | Model 2 | Model 3 | |
| Femoral Neck BMD | 0.000 (0.97) | −0.001 (0.73) | −0.006 (0.70) |
| Lumbar spine BMD | −0.012 (0.41) | −0.012 (0.42) | −0.013 (0.38) |
| Trabecular bone score | 0.003 (0.89) | −0.008 (0.73) | −0.015 (0.48) |
Model 1: Energy-adjusted CML + age + sex + RS-cohorts. Model 2: Model 1 + physical activity + dietary quality score + total energy intake per day. Model 3: Model 2 + eGFR + diabetes status + smoking status + BMI.
Odds ratio of energy-adjusted CML for Major Osteoporotic Fracture (MOF) and vertebral fractures (VFs) in total population with available BMD measurements (N = 3949).
| Major Osteoporotic Fractures (MOFs) | Vertebral Fractures (VFs) | |||
|---|---|---|---|---|
| ORs (95% CI) | ORs (95% CI) | |||
| N (%) |
|
| ||
| Model 1 | 1.08 (0.95–1.24) | 0.23 | 1.13 (0.98–1.27) | 0.06 |
| Model 2 | 1.12 (0.98–1.28) | 0.10 | 1.15 (1.01–1.31) | 0.02 |
| Model 3 | 1.12 (0.98–1.27) | 0.11 | 1.16 (1.01–1.31) | 0.02 |
| Model 4 (BMD) | 1.11 (0.98–1.27) | 0.11 | 1.15 (1.01–1.31) | 0.025 |
Model 1: Energy-adjusted CML + age + sex + RS-cohorts. Model 2: Model 1 + physical activity + dietary quality score + total energy intake per day. Model 3: Model 2 + eGFR + diabetes status + smoking status + BMI. Model 4 Model 3 + femoral neck BMD.
Figure 2Odds ratio (ORs) of energy-adjusted CML for MOF and VFs in non-type 2 diabetics (non-Table 2. DM), diabetics (T2DM), females and males in N = 3949 with complete data on all covariates.
Figure 3Pie chart showing top food categories contributing to dietary CML intake in.
Odds ratio of MOFs and VFs for energy-adjusted CML from the top food categories contributing the total CML intake.
| Major Osteoporotic Fractures (MOFs) | Vertebral Fractures (VFs) | |||
|---|---|---|---|---|
| ORs (95% CI) | ORs (95% CI) | |||
| Sweets | 1.04 (0.80–1.38) | 0.77 | 1.09 (0.83–1.43) | 0.52 |
| Whole grains | 1.02 (0.90–1.17) | 0.73 | 1.02 (0.90–1.15) | 0.78 |
| Milk | 1.06 (0.92–1.18) | 0.51 | 1.09 (0.97–1.22) | 0.15 |
| Unprocessed meat | 1.06 (0.95–1.18) | 0.33 | 1.11 (0.997–1.24) | 0.06 |
| Refined grains | 1.07 (0.94–1.21) | 0.30 | 1.05 (0.94–1.18) | 0.38 |
| Processed meat | 1.40 (0.62–3.12) | 0.42 | 1.74 (0.83–3.67) | 0.15 |
| Nuts | 1.03 (0.29–1.12) | 0.10 | 0.62 (0.32–1.20) | 0.15 |
| Pulses | 0.87 (0.49–1.55) | 0.63 | 1.05 (0.63–1.77) | 0.85 |
| Fish and Seafood | 0.40 (0.12–1.37) | 0.15 | 0.52 (0.16–1.71) | 0.28 |
| Yogurt | 1.21 (0.96–1.54) | 0.11 | 1.14 (0.88–1.48) | 0.33 |
| Top 6 combined | 1.09 (0.97–1.22) | 0.17 | 1.15 (1.03–1.29) |
|
| Top 10 combined | 1.11 (0.98–1.27) | 0.10 | 1.15 (1.01–1.30) |
|
Fully adjusted model: Energy-adjusted CML + age + sex + RS-cohorts + physical activity + dietary quality score + total energy intake per day + eGFR + diabetes status + smoking status + BMI.